Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical testing of trabectedin after platinum therapy in patients with non-small cell lung cancer with advanced over-expresion of XPG and / or ERCC1, and subexpresion of BRCA1 [Ensayo Clinico de Fase II de Trabectedina tras Progresion a Terapia Antitumoral basada en Platino en Pacientes con Cancer No Microcitico de Pulmon (CNMP) Avanzado con Sobreexpresion de XPG y/o ERCC1, y Subexpresion de BRCA1]

Trial Profile

Phase II Clinical testing of trabectedin after platinum therapy in patients with non-small cell lung cancer with advanced over-expresion of XPG and / or ERCC1, and subexpresion of BRCA1 [Ensayo Clinico de Fase II de Trabectedina tras Progresion a Terapia Antitumoral basada en Platino en Pacientes con Cancer No Microcitico de Pulmon (CNMP) Avanzado con Sobreexpresion de XPG y/o ERCC1, y Subexpresion de BRCA1]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms STRACT
  • Sponsors PharmaMar
  • Most Recent Events

    • 09 Apr 2022 Status changed from recruiting to completed.
    • 30 Aug 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top